Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-02-10

Clinical Trial Update: Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of lenalidomide in chronic lymphocytic leukemia patients with residual disease has completed results and posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lenalidomide (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-02-10